Your session is about to expire
← Back to Search
Marqibo for Acute Lymphoblastic Leukemia
Study Summary
This trial is testing a new combination of drugs to treat relapsed acute lymphoblastic leukemia.
- Acute Lymphoblastic Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 175 Patients • NCT01055314Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What risks are present in the utilization of Marqibo?
"Our internal assessment at Power rates the safety of Marqibo as a 1 due to its early stage clinical trial status, indicating limited data supporting both efficacy and security."
Is it possible for me to become involved in this medical experiment?
"This clinical investigation has opened its doors to 36 patients between the age of one and 21, who have been diagnosed with acute lymphoblastic leukemia or mixed phenotypic acute leukemia (with ≥ 5% blasts in marrow) or lymphocytic malignancies. Furthermore, participants must have already recovered from any prior chemotherapy, immunotherapy, or radiotherapy-related toxicity up to Grade 2 severity at baseline. Additionally, Karnofsky performance level should exceed 50%, if aged 16+; Lansky capacity needs to be above 50%, for those younger than 16 years old. Moreover, it is essential that all subjects had reached remission before at least"
Does this research encompass individuals more senior than 35 years of age?
"This research study is searching for participants in the 1-21 age range. Moreover, 591 clinical trials are available to minors and 1321 studies seek seniors as volunteers."
To what medical ailment is Marqibo commonly administered?
"Marqibo is approved for use in treating idiopathic thrombocytopenic purpura and can also offer relief to those suffering from AIDS, advanced thymoma or small cell lung cancer."
How widespread is the implementation of this trial's protocol?
"This trial is currently underway at 31 different hospitals, with the Primary Children's Hospital in Salt Lake City, Sidney Kimmel Cancer Center of Johns Hopkins in Baltimore and Levine Children's Hospital in Charlotte being among them."
What is the highest possible enrollment size for this clinical trial?
"Affirmative. Clinicaltrials.gov data suggests that this clinical trial, which was initially posted on 1/31/2017, is now actively recruiting patients at 31 locations for a total of 36 study participants."
Are researchers still welcoming participants for this experiment?
"Affirmative. According to the clinicaltrials.gov webpage, this trial is actively seeking participants and was initially published on January 31st 2017 with last alteration occurring on April 15th 2020. 36 individuals are needed across a total of 31 clinics for full enrollment in the study."
What other research efforts have been conducted concerning Marqibo?
"Currently, Marqibo is being trialled in 232 investigations. Of these studies, 88 are at Phase 3 and 14551 sites offer this medication. Most of the trials for Marqibo occur within New york City limits."
Share this study with friends
Copy Link
Messenger